contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


medclair-secures-dual-patents-for-new-technology-in-nitrous-oxide-management

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Medclair is a Swedish cleantech company that develops technology for sustainable handling of nitrous oxide in healthcare, recycling and other industries using nitrous oxide. The company has an established international presence and offers solutions that aim to both reduce climate impact and improve the working environment. The headquarters are located in Stockholm.

Medclair

Medclair AB has secured two new patents that enable the handling and destruction of nitrous oxide even in the most demanding hospital environments. By eliminating previous technical limitations...

<div class="mfn-preamble"><p><strong>Medclair AB has secured two new patents that enable the handling and destruction of nitrous oxide even in the most demanding hospital environments. By eliminating previous technical limitations, Medclair can now act as a comprehensive partner for hospitals seeking to eliminate their climate footprint from anesthetic gases, regardless of where in the hospital they are used.</strong></p></div><div class="mfn-body"><p>Previously, mixed anesthetic gases in operating environments have posed a significant challenge, as they risked interfering with or damaging Medclair’s systems. With the new patents, a unique solution is introduced that functions as a smart filter—the system can now capture multiple gases simultaneously. By subsequently releasing the gases in a controlled manner at different temperatures, they can be safely separated. This allows the system to maintain full performance without damage, meaning Medclair can now offer effective nitrous oxide management throughout the entire hospital—from maternity wards to operating theatres. <br><br>The new technology also enables Medclair to capture other anesthetic gases, creating entirely new strategic opportunities. There has been strong interest over time from players working with specific anesthetic gases who wish to incorporate Medclair’s solutions into their offerings. With the new patents in place, Medclair can now move toward active collaboration to meet this demand. <br><br>“With our expertise in nitrous oxide management as a foundation, we can now take the next step and manage the hospital’s overall gas flow. We have long held discussions with partners who want to leverage our infrastructure, and with these new patents, we can now realize these collaborations,” says Jonas Lundh, CEO of Medclair.<br><br><strong>Brief about the patents:</strong> The granted patents relate to Medclair’s innovative zeolite technology for the selective separation of medical gases. The patents are titled: <br><br><a href="https://search.prv.se/#/patent/SE2450532-3" rel="noopener">A METHOD FOR PRODUCING A REVERSIBLE ADSORBENT</a><br><br><a href="https://search.prv.se/#/patent/SE2330449-6" rel="noopener">AN APPARATUS AND A METHOD FOR COLLECTING ANESTHETIC GASES IN AN EXHALATION AIR FROM A PATIENT</a></p></div><div class="mfn-footer mfn-contacts mfn-191fc9f2c137"><p><strong class="mfn-heading-1">Contacts</strong><br><strong>For further information, please contact:</strong><br>Jonas Lundh, Medclair AB (publ), Phone: +46 76 193 90 90, Email: jonas.lundh@medclair.com</p></div><div class="mfn-footer mfn-about mfn-e2a4f0dcf66f"><p><strong class="mfn-heading-1">About Us</strong><br>Medclair is a Swedish cleantech company and a leader in safe and sustainable nitrous oxide management. With operations in twenty countries, Medclair provides innovative solutions that significantly reduce the climate impact of nitrous oxide while improving workplace safety.<br><br>The company is listed on NGM Nordic SME. For more information, please visit <a href="http://www.medclair.com" rel="noopener">www.medclair.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/16860626-cd14-4ac2-9632-10f2a42762ba/medclair-secures-dual-patents-for-new-technology-in-nitrous-oxide-management.pdf" rel="noopener">Medclair secures dual patents for new technology in nitrous oxide management</a></p></div>

Medclair secures dual patents for new technology in nitrous oxide management

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

The DuPont formula helps understand the dynamics of value creation